Neurocrine Biosciences Q4 Earnings Preview: What To Expect After The New Drug Approval
Portfolio Pulse from
Neurocrine Biosciences is expected to show robust sales growth in Q4, driven by the FDA approval of CRENESSITY, a new treatment for CAH. While INGREZZA currently dominates sales, CRENESSITY offers significant growth potential with first-year sales estimates of $150 million. Investors should anticipate volatility around the Q4 earnings report and 2025 guidance, especially concerning CRENESSITY's initial sales figures.
February 04, 2025 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neurocrine Biosciences is poised for robust sales growth in Q4, driven by the FDA approval of CRENESSITY. While INGREZZA is the current sales leader, CRENESSITY's first-year sales are estimated at $150 million, offering significant growth potential. Expect volatility around Q4 earnings and 2025 guidance.
The FDA approval of CRENESSITY is a significant milestone for Neurocrine Biosciences, providing a new revenue stream and growth potential. The anticipation of $150 million in first-year sales for CRENESSITY suggests a positive impact on the company's financials. However, the upcoming Q4 earnings report and 2025 guidance could introduce volatility, especially as investors assess the initial sales figures of CRENESSITY.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100